Baker-Gordon Syndrome-Associated Synaptotagmin-1 Mutations Reduce Synaptic Strength in Mouse Primary and...

Baker-Gordon syndrome (BAGOS) is a neurodevelopmental disorder (NDD) linked to a series of de novo mutations in the synaptic vesicle protein, Synaptotagmin-1 (SYT1). SYT1 is the major calcium sensor for synaptic transmission, and therefore a key molecule in neuronal communication. Several approaches have been used to reveal the underlying molecular mechanisms that lead to BAGOS pathology. While the murine genetic deletion, loss-of-function approach has proven valuable for modeling human diseases, human-induced pluripotent stem cells (hiPSCs) offer a powerful new strategy. In this study, we compare the phenotypes of BAGOS-associated SYT1 mutant variants in murine and human neuron models of either sex. In the well-established murine SYT1 knock-out (KO) model, we found that although all SYT1 mutant variants were correctly localized to the synaptic compartment, none could effectively rescue synaptic transmission. To examine the phenotype of BAGOS-associated SYT1 mutations in the context of human neurons, we generated a SYT1 KO hiPSC line via CRISPR/Cas9 gene editing and used this to derive neurons. As in mouse neurons, SYT1 KO in hiPSCs-derived human neurons strongly impairs synchronous release. Surprisingly, fast synaptic transmission could be rescued to varying extents in the human SYT1 KO model using BAGOS SYT1 mutants. However, overexpression of BAGOS SYT1 mutants in either WT mouse neurons or hiPSC-derived human neurons, a condition closer to the heterozygotic genotype of patients, revealed a dominant-negative effect of the mutant proteins. Our findings suggest that impaired neurotransmitter release efficacy caused by mutations in synaptic proteins may contribute to NDD pathophysiology.